{"id":"pegasys-entecavir","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"10-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-30","effect":"Nausea"},{"rate":"10-20","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegasys (peginterferon alfa-2a) is an interferon that enhances innate and adaptive immune responses to clear HBV-infected cells. Entecavir is a nucleoside reverse transcriptase inhibitor that blocks HBV polymerase and prevents viral replication. Together, they target both viral replication and host immune activation for hepatitis B treatment.","oneSentence":"This combination uses peginterferon alfa-2a to stimulate immune response against hepatitis B virus and entecavir to directly inhibit viral reverse transcriptase, providing dual antiviral activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:52.943Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT04365933","phase":"PHASE2","title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2020-05-25","conditions":"Hepatitis B, Chronic","enrollment":20},{"nctId":"NCT01369199","phase":"PHASE3","title":"Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-05","conditions":"Hepatitis B","enrollment":28},{"nctId":"NCT01368497","phase":"PHASE3","title":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-09","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02726789","phase":"PHASE2","title":"Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Replicor Inc.","startDate":"2012-10","conditions":"Hepatitis B, Chronic","enrollment":5},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT03733652","phase":"NA","title":"Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-11-15","conditions":"Chronic Hepatitis b, Efficacy, Self","enrollment":100},{"nctId":"NCT03272009","phase":"PHASE1","title":"Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects","status":"COMPLETED","sponsor":"Enyo Pharma","startDate":"2017-09-21","conditions":"Hepatitis B, Chronic","enrollment":73},{"nctId":"NCT01938781","phase":"PHASE4","title":"Optimized Treatment and Regression of HBV-induced Liver Fibrosis","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2013-06","conditions":"Liver Fibrosis","enrollment":400},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT02097004","phase":"PHASE4","title":"Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-04","conditions":"Hepatitis B, Chronic","enrollment":111},{"nctId":"NCT03253250","phase":"PHASE4","title":"The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-09-01","conditions":"Chronic Hepatitis b, Hepatic Carcinoma","enrollment":432},{"nctId":"NCT03210467","phase":"","title":"The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B Infection","enrollment":120},{"nctId":"NCT03084250","phase":"PHASE4","title":"The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC","status":"UNKNOWN","sponsor":"Shanghai Nanhui Nanhua Hospital","startDate":"2017-03-10","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT00922207","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-07","conditions":"Hepatitis B, Chronic","enrollment":280},{"nctId":"NCT01706575","phase":"PHASE2","title":"A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-01","conditions":"Hepatitis B, Chronic","enrollment":76},{"nctId":"NCT01179594","phase":"PHASE4","title":"A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2010-09-18","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT00614471","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Hepatitis B, Chronic","enrollment":219},{"nctId":"NCT00940485","phase":"PHASE4","title":"A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Hepatitis B, Chronic","enrollment":200},{"nctId":"NCT02644538","phase":"PHASE4","title":"Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2015-12","conditions":"Hepatitis B","enrollment":196},{"nctId":"NCT02615639","phase":"PHASE1, PHASE2","title":"A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-11","conditions":"Chronic Hepatitis B","enrollment":450},{"nctId":"NCT02589652","phase":"","title":"Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2015-10","conditions":"Chronic Hepatitis B","enrollment":294},{"nctId":"NCT01204762","phase":"PHASE2","title":"Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-11","conditions":"Hepatitis B Virus","enrollment":197},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT01906580","phase":"PHASE4","title":"Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2011-07","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT01925820","phase":"PHASE4","title":"Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-01","conditions":"Chronic Hepatitis B","enrollment":540},{"nctId":"NCT00877760","phase":"PHASE4","title":"Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":184},{"nctId":"NCT01892241","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2010-01","conditions":"Antiviral Treatment of Chronic Hepatitis B","enrollment":74},{"nctId":"NCT00917761","phase":"PHASE4","title":"Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-02","conditions":"Hepatitis B, Chronic","enrollment":300},{"nctId":"NCT00921180","phase":"PHASE4","title":"Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-02","conditions":"Hepatitis B, Chronic","enrollment":148},{"nctId":"NCT01456312","phase":"PHASE4","title":"HBsAg Related Response Guided Therapy","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2012-09","conditions":"Hepatitis B, Chronic","enrollment":200},{"nctId":"NCT01599130","phase":"NA","title":"Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2012-07","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT01589952","phase":"PHASE1, PHASE2","title":"Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2012-03","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT01220596","phase":"PHASE3","title":"Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2010-06","conditions":"Hepatitis B, Chronic","enrollment":228},{"nctId":"NCT00597259","phase":"PHASE4","title":"Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Chronic Hepatitis B","enrollment":294}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No other names"],"phase":"marketed","status":"active","brandName":"Pegasys&Entecavir","genericName":"Pegasys&Entecavir","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses peginterferon alfa-2a to stimulate immune response against hepatitis B virus and entecavir to directly inhibit viral reverse transcriptase, providing dual antiviral activity. Used for Chronic hepatitis B infection, Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}